Phosphodiesterase 4 inhibitors in inflammatory bowel disease: A comprehensive review

Current Pharmaceutical Design

Volumn 16, Issue 33, 2010, Pages 3661-3667

  Salari Sharif, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Crohn's disease; Inflammatory bowel disease; Phosphodiesterase 4 inhibitor; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; AROFYLLINE; CDC 801; CILOMILAST; CYCLIC AMP; CYCLIC GMP; DAXALIPRAM; GAMMA INTERFERON; GELATINASE B; IBUDILAST; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LEUKOTRIENE B4; LEUKOTRIENE C4; NIS 62949; OGLEMILAST; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PROSTAGLANDIN E2; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TETOMILAST; THALIDOMIDE DERIVATIVE; TOFIMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOLOGIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ENTERITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMMUNOMODULATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SLEEP DISORDER; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VOMITING; ANIMAL; METABOLISM; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 79955677653     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210794079209     Document Type: Article

References (110)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33.
2. Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis 2009; 27: 455-64.
3. Jahanshahi G, Motavasel V, Rezaie A, et al. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004; 49(11-12): 1752-7.
4. Dvorak AM, Dickersin GR. Crohns disease: transmission electron microscope studies. Barrier function. Possible changes related to alterations of cell coat, mucous coat, epithelial cells, and paneth cells. Hum Pathol 1980; 11(Suppl): 561-71.
5. Marin ML, Greenstein AJ, Geller SA, Marin RH, Gordon RE, Aufses AH. A freeze fracture study of Crohns disease of terminal ileum: changes in epithelial tight junction and organization. Am J Gastroenterol 1983; 78: 537-47.
6. Kruidenier L, Verspaget HW. Oxidative stress as a pathogenic factor in inflammatory bowel disease- radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015.
7. Kruidenier L, Kuiper I, Lamers CBHW, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semiquantification, localization, and association with mucosal antioxidants. J Pathol 2003; 201: 28-36.
8. Sullivan AJ. Psychogenic factors in ulcerative colitis. Am J Dig Dis Nutr 1936; 2: 651-6.
9. Hart A, Kamm MA. Review article: mechanism of initiation and perpetuation of gut inflammation by stress. Alim Pharmacol Ther 2002; 16: 2017-28.
10. Colón AL, Madrigal JLM, Menchén LA, et al. Stress increases susceptibility to oxidative/nitrosative mucosal damage in an experimental model of colitis in rats. Dig Dis Sci 2004; 49(10): 1713-21.
11. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Tragets 2008; 7(3): 129-35.
12. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-25.
13. Rahimi R, Nikfar, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active crohns disease. Clin Ther 2006; 28: 1983-8.
14. Rezaie A, Taghavi BB, Abdollahi M. Biologic management of fistulating crohns disease. Int J Pharmacl 2005; 1(1): 17-24.
15. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4(2): 185-90.
16. Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53(9): 2524-31.
17. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297(1): 267-79.
18. Iseri SO, Ersoy Y, Ercan F, et al. The effect of sildenafil, a phosphodiesterase-5 inhibitor, on acetic acid-induced colonic inflammation in the rat. J Gastroenterol Hepatol 2009; 24: 1142-8.
19. Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999; 53: 193-229.
20. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 1999; 57: 965-73.
21. Giembycz MA. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 1992; 43: 2041-51.
22. Torphy TJ. Phosphodiesterase isozymes-molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 1998; 157: 351-70.
23. Schudt C, Gantner F, Tenor H, Hatzelmann A. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 1999; 12: 123-29.
24. Torphy TJ, Undem BJ. Phosphodiesterase 4 inhibitors: new opportunities for the treatment of asthma. Thorax 1991; 46: 512-23.
25. Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr Opin Invest Drugs 2000; 1(2): 204-13.
26. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003; 1: 529-41.
27. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neu trophil function by interferon-γ and tumor necrosis factors. J Immunol 1985; 135: 2069-73.
28. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667-71.
29. Thiemermann C, Wu CC, Szabo C, Perretti M, Vane JR. Role of tumor necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol 1993; 110: 177-82.
30. Pender S, Fell JME, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor imunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098-103.
31. Holtmann MH, Douni E, Schutz M, et al. Tumor necrosis factorreceptor 2 is up-regulated on lamina propria T cells in Crohns disease and promotes experimental colitis in vivo. Eur J Immunol 2002; 32(11): 3142-51.
32. Hassan C, Ierardi E, Burattini O, et al. Tumor necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811-7.
33. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of TH1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1: 553-62.
34. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohns disease. J Clin Invest 2001; 107: 695-702.
35. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory crohns disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61: 75-80.
36. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) α increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005; 280(43): 36099-109.
37. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8(14): 1255-96.
38. Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164(2): 1117-24.
39. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997; 18: 164-70.
40. Dyke HJ, Montana JG. The therapeutic potential of PDE4 inhibitors. Exp Opin Invest Drugs 1999; 8(9): 1301-25.
41. Doherty AM. Phosphodiesterase 4 inhibitors as novel antiinflammatory agents. Curr Opin Chem Biol 1999; 3(4): 466-73.
42. Hay DW. Chronic obstructive pulmonary disease: emerging therapies. Curr Opin Chem Biol 2000; 4(4): 412-9.
43. Leckie MJ, Bryan SA, Hansel TT, Barnes PJ. Novel therapy for COPD. Expert Opin Invest Drugs 2000; 9(1): 3-23.
44. Martin TJ. PDE4 inhibitors- a review of the recent patent literature. IDrugs 2001; 4(3): 312-38.
45. Montana JG, Dyke HJ. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Invest Drugs 2002; 11(1): 1-13.
46. Beavo J, Conti M, Heaslip RJ. Multiple cyclic nucleotide phophodiesterases. Mol Pharmacol 1994; 46(3): 399-405.
47. Kohyama T, Liu X, Zhu YK, et al. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol 2002; 27: 487-94.
48. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Pat Endocr Metabol Immun Drug Discov 2009; 3(1): 69-75.
49. Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 1993; 230: 9-14.
50. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibition of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995; 48: 447-57.
51. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998; 63: 101-7.
52. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001; 297: 280-90.
53. Semmler J. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by humen mononuclear Cells. Int J Immunopharmacol 1993; 15: 409-13.
54. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63: 2575-94.
55. Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 2001; 21: 357-64.
56. Banner KH, Hoult JR, Taylor MN, Landells LJ, Page CP. Possible contribution of prostaglandin E2 to the anti-proliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem Pharmacol 1999; 58: 1487-95.
57. Kasyapa CS, Stentz CL, Davey MP, Carr DW. Regulation of IL-15 stimulated TNF-alpha production by rolipram. J Immunol 1999; 163: 2836-43.
58. Hidi R, Timmermans S, Liu E, et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 2000; 15: 342-9.
59. Neilson CP, Vestal RE, Sturm RJ, Heaslip RJ. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990; 86: 801-8.
60. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin stimulated human monocytes by selective PDE isozyme inhibitors. Agents Actions 1993, 39: C77-9.
61. Grishwoal DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. Effect of selective phosphodiesterase type IV inhibitor rolipram on fluid and cellular phases of inflammatory response. Inflammation 1993; 17: 333-44.
62. Peachell PT, Undem BJ, Schleimer RP, et al. Preliminary identification and role of phosphodiesterase isoenzymes in human basophils. J Immunol 1992; 148: 2503-10.
63. Beshay E, Croze F, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 2001; 98: 272-9.
64. MacCluskie K, Klein U, Linnevers C, et al. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J Pharmacol Exp Ther 2006; 319: 468-76
65. Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000; 292(1): 22-30.
66. Maeda T, Sueyoshi S, Aoyama M, et al. Effects of intravenous or oral administration of OPC-6535 in a rat model of 2,4,6- trinitrobenzene sulfonic acid (TNBS)-induced colitis. Gut 1997; 41(Suppl 3): A112.
67. Maeda T, Sato N, Haruta J, et al. Effects of OPC-6535 on a rat model of TNBS-induced colitis: its relation to produced thiobarbituric- reactive substances, IL-1β and TNF-α in the colonic tissue. Ulcer Res 2000; 27: 198-201.
68. Miyakado G, Maeda T, Nagamoto T, Mori M, Tominaga M. Effects of intravenous or oral administration of OPC-6535 in a rat model of dextran sodium sulfate (DSS)-induced colitis. Gut 1997; 41: A227.
69. Barnette MS, Manning CD, Price WJ, Barone FC. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle. J Pharmacol Exp Ther 1993; 264: 801-12.
70. Izzo AA, Mascolo N, Capasso F. Effect of selective phosphodiesterase inhibitors on synaptic transmission in the guinea-pig il eum. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 677-81.
71. Diaz-Granados N, Howe K, Lu J, Derek M. Dextran sulfate sodium- induced colonic histopathology, but not altered epithelial ion transport is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000; 156(6): 2169-77.
72. Videla S, Vilaseca J, Medina C, et al. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 2006; 316(2): 940-5.
73. Loher F, Schmall K, Freytag P, et al. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 2003; 305(2): 549-56.
74. Barone FC, Barton ME, White RF, et al. Deceases stress-induced defecation in rats and mice. Pharmacology 2008; 81: 11-17.
75. Puig J, Salcedo C, Salas A, Fernândez AG, Palacios JM. Curative effects of phosphodiesterase 4 inhibitors in dextran sulfate sodiuminduced colitis in the rat. Gastroenterology 1998; 114: A1064.
76. Ichikawa H, Okamoto S, Kamada N, et al. Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10 deficient mice. Inflamm Bowel Dis 2008; 14: 1483-90.
77. Chihiro M, Nagamoto H, Takamura I, et al. Novel thiazole inhibitors as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J Med Chem 1995; 38: 353-8.
78. Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A. Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs 2007; 16: 1489-506.
79. Nagamoto H, Maeda T, Haruta JP, et al. OPC-6535, a novel oral thiazole compound, suppresses colonic damage in a rat model of TNBS-induced colitis. Gastroenterology 2004; 26: (Suppl 2): M1044.
80. Nagamoto H, Maeda T, Haruta JP, Miyakoda G, Mori T, Tominaga M. OPC-6535 suppresses symptoms and colonic damage in a rat model of DSS-induced chronic colitis. Gastroenterology 2004; 26(Suppl 2): M1045.
81. Banan A, Fitzpatrick L, Zhang Y, Keshavarzian A. OPCcompounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. Free Radic Biol Med 2001; 30: 287-98.
82. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007; 132: 76-86.
83. Togo S, Liu X, Wang X, et al. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-β-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009; 296: L959-L969.
84. Norman TR, Judd FK, Burrows GD. New pharmacological approaches to the management of depression: from theory to clinical practice. Aust N Z J Psychiatry 1992; 26(1): 73-81.
85. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M, Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-90.
86. Hebenstreit GF, Fellerer K, Fiche K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopychiatry 1989; 22: 156-60.
87. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003; 278: 5493-6.
88. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signaling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370: 1-18.
89. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004; 25: 158-63.
90. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005; 11: 129-34.
91. Bethke T, Hartmann M, Baumgartner A, Eichberger C, Hauns B, Wurst W. The new PDE4 inhibitor roflumilast does not influence cardiovascular function (abstract). Am J Respir Crit Care Med 2000; 163: A431.
92. Dastidar SG, Ray A, Shirumalla R, et al. Pharmacology of a novel orally active PDE4 inhibitor. Pharmacology 2009; 83: 275-86.
93. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308-15.
94. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001; 40: 262-69.
95. Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-52.
96. Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 2004; 3: 231-6.
97. Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4 D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123: 25-35.
98. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004; 66: 1679-89.
99. Giembycz MA. Can the anti-inflammatory potential of pDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008; 155: 288-90.
100. Giembycz MA. Phosphodiesterase 4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thor Soc 2005; 2: 326-33.
101. Bodor N, Buchwald P. Soft drig design: general principles and recent applications. Med Res Rev 2000; 20: 58-101.
102. Rahimi R, Ghiasi S, Azimi H, Fakhari S, Abdollahi M. A review of the herbal phosphodiesterase inhibitors; Future perspective of new drugs. Cytokine 2010; 49: 123-9.
103. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci 2009, 54: 471-80.
104. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidantrelated diseases. Inflamm Allergy Drug Targets 2009; 8(1): 2-10.
105. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, Ashtaral-Nakhai L, Minaie B, Abdollahi M. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007, 17: 281-8.
106. Milani E, Nikfar S, Khorasani K, Zamani MJ, Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005, 140(2): 251-5.
107. Abdollahi M, Fooladian F, Emami B, Zafari K, Bahreini- Moghadam A. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol 2003, 22: 587-92.
108. Abdollahi M, Bahreini-Moghadam A, Emami B, Fooladian F, Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium- induced oxidative stress in rat submandibular saliva. Comp Biochem Physiol C Toxicol Pharmacol 2003; 135: 331-6.
109. Houghton LA, Atkinson W, Whorwell PJ, et al. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and PH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two part crossover studies in healthy volunteers. Clin Ther 2006; 28(4): 569-81.
110. Hamblin JN, Angell TDR, Ballantine SP, et al. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008; 18: 4237-41.